Forza Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39M Buy
24,137
+329
+1% +$18.9K 0.43% 59
2026
Q1
$1.44M Buy
23,808
+1,314
+6% +$76.6K 0.5% 50
2025
Q4
$1.21M Buy
22,494
+2,711
+14% +$130K 0.44% 50
2025
Q3
$892K Buy
19,783
+820
+4% +$38.3K 0.34% 70
2025
Q2
$878K Sell
18,963
-1,002
-5% -$49.2K 0.36% 69
2025
Q1
$1.22M Sell
19,965
-110
-0.5% -$6.41K 0.55% 46
2024
Q4
$1.14M Sell
20,075
-548
-3% -$30.6K 0.52% 46
2024
Q3
$1.07M Buy
20,623
+159
+0.8% +$7.46K 0.49% 56
2024
Q2
$850K Hold
20,464
0.44% 61
2024
Q1
$1.11M Sell
20,464
-80
-0.4% -$4.08K 0.58% 52
2023
Q4
$1.05M Sell
20,544
-2,150
-9% -$113K 0.58% 54
2023
Q3
$1.32M Sell
22,694
-200
-0.9% -$12.3K 0.68% 45
2023
Q2
$1.46M Buy
22,894
+345
+2% +$23.1K 0.74% 40
2023
Q1
$1.56M Buy
22,549
+1,967
+10% +$139K 0.8% 31
2022
Q4
$1.48M Buy
+20,582
New +$1.55M 0.98% 31

Other funds holding BMY

Forza Wealth Management's BMY Position: Q2 2026 in Review

Forza Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 1.4% in Q2 2026, buying an estimated $18.9K and bringing the position to 24,137 shares worth $1.39M. The position accounts for 0.43% of the portfolio, ranked #59.

Forza Wealth Management first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.56M in Q1 2023. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Forza Wealth Management held 24,137 shares of Bristol-Myers Squibb worth $1.39M as of Q2 2026.
  • Forza Wealth Management bought 329 Bristol-Myers Squibb shares in Q2 2026, an estimated $18.9K.
  • Bristol-Myers Squibb made up 0.43% of Forza Wealth Management's portfolio in Q2 2026, its #59 holding.
  • Forza Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
  • Forza Wealth Management's Bristol-Myers Squibb position peaked at $1.56M in Q1 2023.
  • 879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Forza Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.